Sajjan Rajpoot

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Molecular Dynamics Simulations

Angiotensin Converting Enzyme

Protein Protein

Top Venues

Future medicinal chemistry

Future virology

This page only lists publications with an associated author ORCID identifier.

Publications

Sajjan Rajpoot, Ashutosh Kumar, Vadim Gaponenko, Teresa Lm Thurston, Dolly Mehta, Syed M Faisal, Kam Yj Zhang, Hem C Jha, Gajanan N Darwhekar, Mubashir Baig Mirza
Dorzolamide suppresses PKCδ -TIRAP-p38 MAPK signaling axis to dampen the inflammatory response. Future medicinal chemistry (2023)
Kundan Solanki, Sajjan Rajpoot, Ashutosh Kumar, Kam Y J Zhang, Tomokazu Ohishi, Nik Hirani, Khandu Wadhonkar, Pramod Patidar, Qiuwei Pan, Mubashir Baig Mirza
Structural analysis of spike proteins from SARS-CoV-2 variants of concern highlighting their functional alterations. Future virology (2022)
Yining Wang, Sajjan Rajpoot, Pengfei Li, Marla Lavrijsen, Zhongren Ma, Nik Hirani, Uzma Saqib, Qiuwei Pan, Mubashir Baig Mirza
Repurposing dyphylline as a pan-coronavirus antiviral therapy. Future medicinal chemistry 14 (10) (2022)
Tomokazu Ohishi, Takayuki Hishiki, Mirza S Baig, Sajjan Rajpoot, Uzma Saqib, Tomohiko Takasaki, Yukihiko Hara
Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2. PloS one 17 (7) (2022)
Sajjan Rajpoot, Tomokazu Ohishi, Ashutosh Kumar, Qiuwei Pan, Sreeparna Banerjee, Kam Y J Zhang, Mirza S Baig
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Drugs in R&D 21 (3) (2021)